Department of Error (DOI:10.1016/S0140-6736(08)61619-0);Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

The Lancet

Volumn 372, Issue 9648, 2008, Pages 1463-1472

  Kappos, Ludwig ^a   Gold, Ralf ^b   Miller, David H ^c   MacManus, David G ^c   Havrdova, Eva ^d   Limmroth, Volker ^e   Polman, Chris H ^f   Schmierer, Klaus ^c   Yousry, Tarek A ^c   Yang, Minhua ^g   Eraksoy, Mefkûre ^h   Meluzinova, Eva ⁱ   Rektor, Ivan ^j   Dawson, Katherine T ^g   Sandrock, Alfred W ^g   O'Neill, Gilmore N ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g BIOGEN   (United States)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j MASARYK UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BG 00012; FUMARIC ACID; GADOLINIUM; METHYLPREDNISOLONE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BRAIN DAMAGE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; INFLUENZA; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIC INFLAMMATORY DISEASE; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; URTICARIA; UTERUS MYOMA; VERTIGO; VOMITING;

EID: 54149116366     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60776-5     Document Type: Erratum

References (36)

1. Lukashev M., Zeng W., Ryan S., et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethyl fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities. Mult Scler 13 suppl 2 (2007) S149
2. Itoh K., Chiba T., Takahashi S., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236 (1997) 313-322
3. Venugopal R., and Jaiswal A.K. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17 (1998) 3145-3156
4. Chen X.L., Dodd G., Thomas S., et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 290 (2006) H1862-H1870
5. Calabrese V., Ravagna A., Colombrita C., et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 79 (2005) 509-521
6. Li J., Johnson D., Calkins M., Wright L., Svendsen C., and Johnson J. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83 (2005) 313-328
7. Satoh T., Okamato S.I., Cui J., et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducers. Proc Natl Acad Sci USA 103 (2006) 768-773
8. Vargas M.R., Pehar M., Cassina P., et al. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survival. J Biol Chem 27 (2005) 25571-25579
9. Zhao C., Zawadzka M., Roulois A.J., Bruce C.C., and Franklin R.J. Promoting remyelination in multiple sclerosis by endogenous adult neural stem/precursor cells: defining cellular targets. J Neurol Sci 265 (2008) 12-16
10. Hubbs A.F., Benkovic S.A., Miller D.B., et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 170 (2007) 2068-2076
11. Wierinckx A., Brevé J., Mercier D., Schultzberg M., Drukarch B., and Van Dam A.M. Detoxification enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 166 (2005) 132-143
12. Loewe R., Pillinger M., de Martin R., et al. Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-κB-dependent manner. J Invest Dermatol 117 (2001) 1363-1368
13. Schilling S., Goelz S., Linker R., Luehder F., and Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145 (2006) 101-107
14. Altmeyer P.J., Matthes U., Pawlak F., et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30 (1994) 977-981
15. Schimrigk S., Brune N., Hellwig K., et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13 (2006) 604-610
16. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50 (2001) 121-127
17. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
18. Kappos L., Lechner-Scott J., and Lienert C. Interactive training DVD-ROM for a standardised, quantified neurological examination and assessment of Kurtzke's Functional Systems and Expanded Disability Status Scale in multiple sclerosis (2003), Point de Vue Audiovisuelle Produktionen, Basel, Switzerland. http://www.neurostatus.net/training (accessed Jan 4, 2008).
19. Sormani M.P., Rovaris M., Bagnato F., et al. Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. Neurology 57 (2001) 1883-1885
20. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., and McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34 (1993) 661-669
21. Brück W., Bitsch A., Kolenda H., Brück Y., Stiefel M., and Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 42 (1997) 783-793
22. Kappos L., Moeri D., Radue E.W., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353 (1999) 964-969
23. O'Connor P., Miller D., Riester K., et al., International Natalizumab Trial Group. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler 11 (2005) 568-572
24. Richert N.D., Howard T., Frank J.A., et al. Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 66 (2006) 551-556
25. van Walderveen M., Barkhof F., Pouwels P.J.W., van Schijndel R.A., Polman C.H., and Castelijns J.A. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46 (1999) 79-87
26. Bo L., Dawson T.M., Wesselingh S., et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36 (1994) 778-786
27. van der Goes A., Brouwer J., Hoekstra K., Roos D., van den Berg T.K., and Dijkstra C.D. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 92 (1998) 67-75
28. Barnes J., and Karin M. Nuclear factor kappa B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 (1997) 1066-1071
29. LeVine S.M. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypothesis 39 (1992) 271-274
30. Zagórski T., Dudek I., Berkan L., Mazurek M., Kedziora J., and Chmielewski H. Superoxide dismutase (SOD-1) activity in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 25 (1991) 725-730
31. Langemann H., Kabiersch A., and Newcombe J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 32 (1992) 248-252
32. Liu Y., Zhu B., Wang X., et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J Neuroimmunol 139 (2003) 27-35
33. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
34. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45 (1995) 1268-1276
35. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
36. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 352 (1998) 1498-1504